Sucram Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2013
- Open Charges ₹ 2.74 Cr
About Sucram Pharmaceuticals
Sucram Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 September 2006 and has a history of 18 years and four months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2013. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.74 Cr.
Pravinkumar Sangeetha and Thangavel Pravinkumar serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U02423TN2006PTC061198
-
Company No.
061198
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Sep 2006
-
Date of AGM
30 Sep 2013
-
Date of Balance Sheet
31 Mar 2013
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sucram Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravinkumar Sangeetha
|
Director | 26-Sep-2006 | Current |
|
Thangavel Pravinkumar
|
Director | 26-Sep-2006 | Current |
Financial Performance of Sucram Pharmaceuticals.
Enhance accessibility to Sucram Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sucram Pharmaceuticals?
Unlock access to Sucram Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹27.40 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 2.20 Cr
- Canara Bank : 0.54 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Feb 2013 | Indian Bank | ₹2.20 Cr | Open |
| 12 Aug 2009 | Canara Bank | ₹0.40 M | Open |
| 22 Aug 2007 | Canara Bank | ₹5.00 M | Open |
How Many Employees Work at Sucram Pharmaceuticals?
Unlock and access historical data on people associated with Sucram Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sucram Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sucram Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.